Clinical trial
A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.
NCT01470053 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.
- Lead sponsor
- Hanlim Pharm. Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- November 30, 2012
- Enrollment
- 347 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
perennial allergic rhinitis